Moderna announces clinical and program updates at 3rd annual vaccines day

Covid-19 vaccine phase 2/3 study in children 6 months to under 6 years has successfully met its primary endpoint with robust neutralizing antibody titers similar to adults. moderna is moving forward with global regulatory submissions for mrna-1273 for primary vaccination of children 6 months to under 6 years of age.
MRNA Ratings Summary
MRNA Quant Ranking